GenVec and Fuse Pharmaceutical Industries entered into a 3-year sponsored research collaboration to identify a targeted cancer therapy to treat both primary and metastasized tumors. The therapy incorporates tumor necrosis factor alpha (TNF-alpha, an anticancer protein) gene, to enable the production of TNF-alpha at the disease site.